Trial · NCT01791153
Participant flow48
How many started, completed or left each group, period by period.
1 to 20 of 48
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Part 1: Blinded Period | STARTED | Part 1: Tocilizumab qw + 26 Weeks Prednisone Taper | 100 | |
| Part 1: Blinded Period | STARTED | Part 1: Tocilizumab q2w + 26 Weeks Prednisone Taper | 49 | |
| Part 1: Blinded Period | STARTED | Part 1: Placebo + 26 Weeks Prednisone Taper | 50 | |
| Part 1: Blinded Period | STARTED | Part 1: Placebo + 52 Weeks Prednisone Taper | 51 | |
| Part 1: Blinded Period | STARTED | Part 2: No Tocilizumab (Placebo in Part 1) | 0 | |
| Part 1: Blinded Period | STARTED | Part 2: No Tocilizumab (Tocilizumab in Part 1) | 0 | |
| Part 1: Blinded Period | STARTED | Part 2: Tocilizumab (Placebo in Part 1) | 0 | |
| Part 1: Blinded Period | STARTED | Part 2: Tocilizumab (Tocilizumab in Part 1) | 0 | |
| Part 1: Blinded Period | COMPLETED | Part 1: Tocilizumab qw + 26 Weeks Prednisone Taper | 85 | |
| Part 1: Blinded Period | COMPLETED | Part 1: Tocilizumab q2w + 26 Weeks Prednisone Taper | 41 | |
| Part 1: Blinded Period | COMPLETED | Part 1: Placebo + 26 Weeks Prednisone Taper | 44 | |
| Part 1: Blinded Period | COMPLETED | Part 1: Placebo + 52 Weeks Prednisone Taper | 46 | |
| Part 1: Blinded Period | COMPLETED | Part 2: No Tocilizumab (Placebo in Part 1) | 0 | |
| Part 1: Blinded Period | COMPLETED | Part 2: No Tocilizumab (Tocilizumab in Part 1) | 0 | |
| Part 1: Blinded Period | COMPLETED | Part 2: Tocilizumab (Placebo in Part 1) | 0 | |
| Part 1: Blinded Period | COMPLETED | Part 2: Tocilizumab (Tocilizumab in Part 1) | 0 | |
| Part 1: Blinded Period | NOT COMPLETED | Part 1: Tocilizumab qw + 26 Weeks Prednisone Taper | 15 | |
| Part 1: Blinded Period | NOT COMPLETED | Part 1: Tocilizumab q2w + 26 Weeks Prednisone Taper | 8 | |
| Part 1: Blinded Period | NOT COMPLETED | Part 1: Placebo + 26 Weeks Prednisone Taper | 6 | |
| Part 1: Blinded Period | NOT COMPLETED | Part 1: Placebo + 52 Weeks Prednisone Taper | 5 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01791153/flow